Xianglin Wu

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
    Breast Cancer Res 13:R27. 2011
  2. pmc Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens
    John R Hawse
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e54613. 2013
  3. doi request reprint The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:1722-7. 2009
  4. pmc Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 113:711-23. 2012

Detail Information

Publications4

  1. pmc Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
    Breast Cancer Res 13:R27. 2011
    ..Here, we characterize the molecular actions of endoxifen in breast cancer cells expressing ERβ and examine its effectiveness as an anti-estrogenic agent in these cell lines...
  2. pmc Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens
    John R Hawse
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e54613. 2013
    ....
  3. doi request reprint The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:1722-7. 2009
    ..These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer...
  4. pmc Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 113:711-23. 2012
    ..The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy...